(This story is part of the cover package in the July issue of MJBizMagazine.)
The goal of a cannabis research study doesn’t always have to be the creation of a drug approved by the U.S. Food and Drug Administration.
“I would argue that even though we’re not cranking out a drug on the other end, the arguments for doing something like this are multifold,” said Dr. Stephen Dahmer, chief medical officer at Vireo Health, a Minnesota-based multistate operator that, over the past several years, has partnered with universities on several studies exploring the therapeutic benefits of cannabis.
ADVERTISEMENT
Dahmer said arguments for carrying out research studies include:
Building consumer trust in a brand. Getting “buy-in” from the medical profession. Understanding how patients respond to cannabis treatments.
Vireo – whose parent company, Goodness Growth Holdings, agreed to be acquired by Verano Holdings – considered undertaking an FDA-approved study.
Read full article on Marijuana Business Daily
